Shots:
- Part B of P-II (APEX) trial assessed high, medium, or low-dose zumilokibart vs PBO in 346 pts, where mid & high-doses met the 1EP at 16wks., with 61.6% pts on high dose, 65.9% on mid-dose & 50.5% on low dose achieved EASI-75 vs 23.4% on PBO
- At Wk. 16, mid-dose also met key 2EP with IGA 0/1 response in 46% vs 10.9%, EASI-90 in 47.4% vs 9.3%, I-NRS ≥4 reduction in 50.5% vs 13.9%, EASI-100 in 16.5% vs 3.4%, & vLDA response in 20.6% vs 4.5% of pts
- Apogee plans to advance the mid-dose zumilokibart into P-III (Adventure 1 & 2) trials for mod. to sev. AD in H2’26, pending regulatory interactions, while also initiating P-II trial for asthma in H1’27 & eosinophilic esophagitis in H2’26
Ref: Globenewswire | Image: Apogee | Press Release
Related News: Apogee Therapeutics Secures Up to $1.3B Financing from Blackstone to Advance Zumilokibart
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
